Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with substrate reduction therapy.

Atul Mehta1

  • 1Royal Free and University College Medical School, London, UK.

European Journal of Internal Medicine
|October 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flexible Bronchoscopy in the Intensive Care Unit: Controversies, Clinical Applications, and the Expanding Role of Intensivists.

Journal of clinical medicine·2026
Same author

Non-Anastomotic Bronchial Stenosis Leading to Dual Lobar Collapse and Ex Vacuo Pleural Effusion: A Case Report.

Transplantation proceedings·2026
Same author

Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Detection of PET-CT Negative Contralateral Hilar Lymph Node Metastasis in the Staging of Non-small cell Lung Cancer.

Journal of bronchology & interventional pulmonology·2026
Same author

Allograft and recipient tissue injury during cardiac allograft rejection: Evidence from cell-free DNA.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Interstitial Lung Disease in 2025-Progress, Challenges, and Hope Ahead.

Journal of clinical medicine·2025
Same author

Kaposi Sarcoma in Two Lung Transplant Recipients: A Single-Center Experience.

Transplantation proceedings·2024
Same journal

Severe hyperkalaemia during liposomal amphotericin B treatment, independent of nephrotoxicity.

European journal of internal medicine·2026
Same journal

Cardiovascular complications of antineoplastic treatment in prostate cancer patients and compensatory strategies for clinical management.

European journal of internal medicine·2026
Same journal

Artificial intelligence and clinical responsibility in the multimorbid patient.

European journal of internal medicine·2026
Same journal

Risk reclassification and implementation challenges in the 2026 AHA/ACC pulmonary embolism guideline.

European journal of internal medicine·2026
Same journal

Recurrent Pericarditis, Hydroxychloroquine, and the Unrecognized Risk of Myasthenia Gravis.

European journal of internal medicine·2026
Same journal

Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: promise, pitfalls, and unanswered questions.

European journal of internal medicine·2026
See all related articles

Substrate reduction therapy (SRT) with miglustat offers an effective oral alternative for type 1 Gaucher

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Enzyme replacement therapy (ERT) successfully manages hematologic and organomegaly symptoms in type 1 Gaucher's disease.
  • ERT has limitations in addressing long-term skeletal and neurological complications.
  • Current ERT involves intravenous administration, which is not suitable for all patients.

Purpose of the Study:

  • To evaluate substrate reduction therapy (SRT) using miglustat as an alternative treatment for type 1 Gaucher's disease.
  • To assess the efficacy of oral miglustat in patients previously treated with ERT.

Main Methods:

  • Six patients with type 1 Gaucher's disease, previously on ERT, were switched to oral miglustat.
  • Treatment decisions were guided by the European Working Group on Gaucher's disease guidelines.

Related Experiment Videos

  • Miglustat functions by inhibiting glucocerebroside synthesis, contrasting with ERT's degradation acceleration.

    • Main Results:

    • Initial experience indicates that oral miglustat is an effective alternative treatment.
    • Miglustat provides a viable option for patients for whom ERT is unsuitable.
    • SRT offers a different therapeutic mechanism by preventing substrate accumulation.

    Conclusions:

    • Oral miglustat (Zavesca®) presents a valuable therapeutic choice for type 1 Gaucher's disease patients.
    • SRT complements ERT by offering an alternative mechanism and administration route.
    • Further research and global accessibility are crucial for advancing Gaucher's disease treatment.